Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment.

Autor:	Falkson, Geoffrey, Dyk, J., Stapelberg, René, Falkson, H., Falkson, G, Van Dyk, J J, Stapelberg, R, Falkson, H C
Předmět:	KIDNEY disease prevention SULFUR compounds BLADDER diseases CLINICAL trials COMPARATIVE studies ETHANOL KIDNEY diseases LEUCOPENIA RESEARCH methodology MEDICAL cooperation RESEARCH TUMORS EVALUATION research CYCLOPHOSPHAMIDE IFOSFAMIDE PREVENTION THERAPEUTICS
Zdroj:	Cancer Chemotherapy & Pharmacology; Jan1982, Vol. 9 Issue 2, p81-84, 4p
Abstrakt:	Thirty-two patients with advanced cancer were treated in a phase I-II trial with ifosfamide plus mesnum. At doses up to 300 mg ifosfamide/kg the administration of mesnum prevented most of the expected kidney and bladder toxicity. With this high dose range hemopoietic dose-limiting. Only one of twelve evaluable patients with breast cancer showed definite therapeutic benefit. Complete remission or partial remission was seen in three patients with non-Hodgkin lymphoma and one patient with Hodgkin's disease. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink